Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Healiva buys critical cell therapy manufacturing assets from B. Braun

By Sean Whooley | November 21, 2022

Healiva LogoHealiva announced today that it acquired critical manufacturing assets from B. Braun’s B. Braun Medical AG Switzerland affiliate.

The companies declined to disclose financial details for the acquisition.

Lugano, Switzerland-based Healiva develops precision medicine for patients with chronic and acute wounds. It acquired a qualified cell bank for the manufacturing of its first cell therapy product.

The company said in a news release that the cell bank is “essential” for the GMP-compliant manufacturing of EpiDex. It designed EpiDex as an autologous epidermis derived from the patients own hair cells.

“This transaction will enable Healiva to accelerate the launch of EpiDex, which is projected for Q4 2023,” said Priyanka Dutta-Passecker, co-founder and CEO of Healiva. “This will allow us to deliver our clinically proven, surgery-free solution to patients with severe chronic wounds more promptly, shortening the path to market for EpiDex by approximately one year.”

EpiDex offers a means to treat chronic venous leg ulcers and other chronic wounds, according to Healiva. The company says it is “as effective as surgery” for severe chronic wounds. However, it provides improved const-effectiveness and patients prefer it, the company noted.

The platform holds approval for the Swiss market. Healiva plans to initially launch it in Switzerland, pending Swissmedic approval. Following that, it plans to launch in Germany and other EMEA countries.

“The acquisition of a qualified fibroblast cell bank that meets the regulatory requirements for Advanced Therapy Medicinal Products (ATMPs) and has previously been approved for the commercial production of EpiDex is a key step in Healiva’s product development,” said Dr. Andreas Emmendoerffer clinical advisor at Healiva.

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE